Offer - Urjas Oil for just ₹ 1
Restofos 70 Mg Tablet, a prescription drug, is manufactured in various forms such as Tablet. Osteoporosis are some of its major therapeutic uses. Restofos 70 Mg Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Restofos 70 Mg Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Restofos 70 Mg Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Restofos 70 Mg Tablet go away soon, and do not persist beyond the duration of the treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
Restofos 70 Mg Tablet's effect during pregnancy is Mild and Unknown while nursing. It is important to know if Restofos 70 Mg Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Restofos 70 Mg Tablet related warnings section.
Some other conditions that can be affected by Restofos 70 Mg Tablet are listed in the contraindications section below.
Besides this, Restofos 70 Mg Tablet may also have severe interaction with some medicines. See below for a complete list.
In addition to these precautions, you may also note that Restofos 70 Mg Tablet is safe while driving, and is is addictive in nature.
Restofos 70 Mg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult(Female) |
|
| Geriatric |
|
Is the use of Restofos 70 Mg Tablet safe for pregnant women?
Pregnant women may get mild side effects from Restofos.
Is the use of Restofos 70 Mg Tablet safe during breastfeeding?
Due to lack of research work on this topic, the side effects of Restofos for breastfeeding women are not known.
What is the effect of Restofos 70 Mg Tablet on the Kidneys?
Restofos has very mild side effects on the kidneys.
What is the effect of Restofos 70 Mg Tablet on the Liver?
Restofos may have severe effects on your liver, so do not take it without first consulting your doctor.
What is the effect of Restofos 70 Mg Tablet on the Heart?
Effects of Restofos on heart can be severe. It is not safe to use without doctor's advice.
If you are suffering from any of the following diseases, you should not take Restofos 70 Mg Tablet unless your doctor advises you to do so -
Is this Restofos 70 Mg Tablet habit forming or addictive?
Forming a habit of Restofos 70 Mg Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Restofos 70 Mg Tablet does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Restofos 70 Mg Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Restofos 70 Mg Tablet for mental disorders.
Interaction between Food and Restofos 70 Mg Tablet
Taking Restofos 70 Mg Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Restofos 70 Mg Tablet
Drinking alcohol while taking Restofos 70 Mg Tablet may lead to slight side effects. If you experience any side effects, contact your doctor.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Fosamax® (alendronate sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 345
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 121-123
